The latest price target for Serina Therapeutics (AMEX:SER) was reported by Jones Trading on March 11, 2025. The analyst firm set a price target for $11.00 expecting SER to rise to within 12 months (a possible 131.58% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Serina Therapeutics (AMEX:SER) was provided by Jones Trading, and Serina Therapeutics initiated their buy rating.

There is no last upgrade for Serina Therapeutics

There is no last downgrade for Serina Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Serina Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Serina Therapeutics was filed on March 11, 2025 so you should expect the next rating to be made available sometime around March 11, 2026.

While ratings are subjective and will change, the latest Serina Therapeutics (SER) rating was a initiated with a price target of $0.00 to $11.00. The current price Serina Therapeutics (SER) is trading at is $4.75, which is within the analyst’s predicted range.